0001118072 false true FY 2023 --12-31 true true 0

 447201 473057

 2023-01-01

 2023-06-30

 2024-03-31

 2022-01-01

 2021-12-31

 2021-12-31

 2021-12-31

 2021-12-31

 2022-01-01

 2022-01-01

 2022-01-01

 2023-01-01

 2023-01-01

 2023-01-01

 UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

 Washington, D.C. 20549

 FORM 10-K

 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the fiscal year ended December
31, 2023

 TRANSITION REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For transition period ___ to ___

 Commission file number: 000-30991

 SKINOVATION PHARMACEUTICAL INCORPORATED

 (Exact name of registrant as specified in its charter)

 Wyoming

 (State or other jurisdiction of incorporation or organization)

 87-0458170

 (I.R.S. Employer Identification No.)

 440 East 400 South Ste 300, Salt Lake City, Utah

 (Address of principal executive offices)

 84111

 (Zip Code)

 Registrant's telephone number, including area code: (801) 323-2395

 Securities registered pursuant to Section 12(b) of the Act: None

 Securities registered under Section 12(g) of the Act: Common Stock

 Indicate by check mark if the registrant is a well-known seasoned issuer,
as defined in Rule 405 of the Securities Act. Yes No

 Indicate by check mark if the registrant is not required to file reports
pursuant to Section 13 or 15(d) of the Exchange Act. Yes No

 Indicate by check mark whether the registrant (1) filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the
past 90 days. Yes No

 Indicate by check mark whether the registrant has submitted electronically
every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

 Indicate by check mark whether the registrant is a large accelerated filer,
an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large
accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company"
in Rule 12b-2 of the Exchange Act.

 Large accelerated filer

 Non-accelerated filer

 Accelerated filer

 Smaller reporting company

 Emerging growth company

 If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.

 Indicate by checkmark whether the registrant has filed a report on
and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under
Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its
audit report.

 If securities are registered pursuant to Section
12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction
of an error to previously issued financial statements.

 Indicate by check mark whether any of those error corrections are
restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers
during the relevant recovery period pursuant to §240.10D-1(b).

 Indicate by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Exchange Act). Yes No

 The registrant did not have an active trading market for its Common Stock
as of the last business day of its most recently completed second fiscal quarter; therefore, an aggregate market value of shares of voting
and non-voting common equity held by non-affiliates cannot be determined.

 The number of shares outstanding of the registrant's Common Stock
as of March 31, 2024, was 708,000.

 Documents incorporated by reference: None

 Item 1.

 Business

 Item 1A.

 Risk Factors

 Item 1B.

 Unresolved Staff Comments

 Item 1C.

 Cybersecurity

 Item 2.

 Properties

 Item 3.

 Legal Procedures

 Item 4.

 Mine Safety Disclosure

 Item 5.

 Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchased of
 Equity Securities

 Item 6.

 Selected Financial Data

 Item 7.

 Management's Discussion and Analysis of Financial Condition and Results of Operations

 Item 8.

 Financial Statements and Supplementary Data

 Item 9.

 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 Item 9A.

 Controls and Procedures

 Item 9B.

 Other Information

 Item 10.

 Directors, Executive Officers and Corporate Governance

 Item 11.

 Executive Compensation

 Item 12.

 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 Item 13.

 Certain Relationships and Related Transactions, and Director Independence

 Item 14.

 Principal Accounting Fees and Services

 Item 15.

 Exhibits, Financial Statement Schedules

 Signatures

 In this annual report references to "Skinovation," "we,"
"us," "our" and "the Company" refer to Skinovation Pharmaceutical Incorporated.

 FORWARD LOOKING STATEMENTS

 The U. S. Securities and Exchange Commission ("SEC")
encourages companies to disclose forward-looking information so that investors can better understand future prospects and make informed
investment decisions. This report contains these types of statements. Words such as "may," "expect," "believe,"
"anticipate," "estimate," "project," or "continue" or comparable terminology used in connection
with any discussion of future operating results or financial performance identify forward-looking statements. You are cautioned not to
place undue reliance on the forward-looking statements, which speak only as of the date of this report. All forward-looking statements
reflect our present expectation of future events and are subject to a number of important factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking statements.

 ITEM 1. BUSINESS

 Historical Development

 The Company was originally incorporated in the state
of Nevada on January 15, 1988, as Data Financial Corporation. On August 5, 1992, Data Financial changed its name to Skinovation Pharmaceutical
Incorporated when it began operations as a licensee for pharmaceutical products; however, that operation ceased in 1993. On November 23,
2016, the Company filed Articles of Domestication in the state of Wyoming; effectively moving the Company's state of domicile from
Nevada to Wyoming.

 Our Business Plan

 Our business plan is to seek, investigate, and, if
warranted, acquire an interest in a business opportunity. Our acquisition of a business opportunity may be made by asset acquisition,
merger, exchange of stock, or otherwise. We have very limited sources of capital, and we probably will only be able to take advantage
of one business opportunity. As of the date of this filing, we have not identified any business opportunity that we plan to pursue, nor
have we reached any preliminary or definitive agreements or understandings with any person concerning an acquisition or merger.

 Based upon current economic conditions, management
believes that it is possible, if not probable, for a company like ours, without many assets or liabilities, to negotiate a merger or acquisition
with a viable private company. The opportunity arises principally because of the expensive legal and accounting fees and the length of
time associated with the registration process of "going public."

 Our search for a business opportunity will not be
limited to any particular geographical area or industry and includes both U.S. and international companies. Our management has unrestricted
discretion in seeking and participating in a business opportunity, subject to the availability of such opportunities, economic conditions
and other factors. Our management believes that companies who desire a public market to enhance liquidity for current stockholders, or
plan to acquire additional assets through issuance of securities rather than for cash, will be potential merger or acquisition candidates.

 The selection of a business opportunity in which to
participate is complex and extremely risky and will be made by management in the exercise of their business judgment. Our activities are
subject to several significant risks which arise primarily as a result of the fact that we have no operating business and may acquire
or participate in a business opportunity based on the decision of management which will, in all probability, act without consent, vote,
or approval of our stockholders. We cannot assure you that we will be able to identify and merge with or acquire any business opportunity
which will ultimately prove to be beneficial to Skinovation and our stockholders. Should a merger or acquisition prove unsuccessful, it
is possible management may decide not to pursue further acquisition activities and management may abandon our search and we may become
dormant or be dissolved.

 It is possible that the range of business opportunities
that might be available for consideration by us could be limited by the fact that our Common Stock currently is not listed on any established
public trading market. We cannot assure you that a market will develop or that a stockholder will be able to liquidate his/her/its investments
without considerable delay, if at all. If a market develops, our shares will likely be subject to the rules of the Securities Enforcement
Remedies and Penny Stock Reform Act of 1990. The liquidity of penny stock is affected by specific disclosure procedures required by those
rules to be followed by all broker-dealers, including but not limited to, determining the suitability of the stock for a particular customer,
and obtaining a written agreement from the customer to purchase the stock. This rule may affect the ability of broker-dealers to sell
our securities and may affect the ability of purchasers to sell our securities in any market.

 Investigation and Selection of Business Opportunities

 We anticipate that business opportunities will come
to our attention from various sources, including our officers and Directors, our stockholders, professional advisors such as attorneys
and accountants, securities broker-dealers, investment banking firms, venture capitalists, members of the financial community and others
who may present unsolicited proposals. Management expects that prior personal and business relationships may lead to contacts with these
various sources.

 We expect that our due diligence will encompass, among
other things, meetings with the target business's incumbent management and inspection of its facilities, as necessary, as well as
a review of financial and other information which is made available to our management. This due diligence review may be conducted either
by our management or by unaffiliated third parties we may engage. Our limited funds and the lack of full-time management will likely make
it impracticable to conduct a complete and exhaustive investigation and analysis of a target business before we consummate a business
combination. We anticipate that we will rely upon funds provided by loans from management and/or significant stockholders to conduct investigation
and analysis of any potential target companies or businesses. We may also rely upon the issuance of our Common Stock in lieu of cash payments
for services or expenses related to any analysis. Management decisions, therefore, will likely be made without detailed feasibility studies,
independent analysis, market surveys and the like which, if we had more funds available to us, would be desirable. We will be particularly
dependent in making decisions upon information provided by the promoters, owners, sponsors or other persons associated with the target
business seeking our participation.

 Our management will analyze the business opportunities;
however, none of our management team are professional business analysts (See Part III, Item 10, below). Our management has had limited
experience with mergers and acquisitions of business opportunities and has not been involved with an initial public offering. Due to management's
limited experience with mergers and acquisitions, they may rely on principal stockholders or associates, or promoters or their affiliates
to assist in the investigation and selection of business opportunities.

 Certain conflicts of interest exist or may develop
between us and our executive officers and Directors. They have other business interests to which they currently devote attention, which
include a medical practice and independent contractor services (See Part III, Item 10, below.) Our management may be expected to continue
to devote their attention to these other business interests although management time should be devoted to our business. As a result, conflicts
of interest may arise that can be resolved only through their exercise of judgment in a manner which is consistent with their fiduciary
duties to us.

 A decision to participate in a specific business opportunity
may be made upon our management's analysis of:

 •
 the quality of the business opportunity's management and personnel,

 •
 the anticipated acceptability of its new products or marketing concept,

 •
 the merit of its technological changes,

 •
 the perceived benefit that it will derive from becoming a publicly held entity, and

 •
 numerous other factors which are difficult, if not impossible, to analyze through the application of any
objective criteria.

 No one factor described above will be controlling
in the selection of a business opportunity. Management will attempt to analyze all factors appropriate to each opportunity and make a
determination based upon reasonable investigative measures and available data. Potential business opportunities may occur in many different
industries and at various stages of development. Thus, the task of comparative investigation and analysis of such business opportunities
will be extremely difficult and complex. Potential investors must recognize that because of our limited capital available for investigation
and management's limited experience in business analysis, we may not discover or adequately evaluate adverse facts about the business
opportunity to be acquired.

 In many instances, we anticipate that the historical
operations of a specific business opportunity may not necessarily be indicative of the potential for the future operations because of
the possible need to substantially shift marketing approaches, significantly expand operations, change product emphasis, change or substantially
augment management, or make other changes. We will be dependent upon the owners of a business opportunity to identify any such problems
which may exist and to implement, or be primarily responsible for, the implementation of required changes.

 Form of Acquisition

 We cannot predict the manner in which we may participate
in a business opportunity. Specific business opportunities will be reviewed as well as our needs and desires and those of the promoters
of the opportunity. The legal structure or method deemed by management to be suitable will be selected based upon our review and our relative
negotiating strength. We may be required to merge, consolidate or reorganize with other corporations or forms of business organizations.
In addition, our present management and stockholders most likely will not have control of a majority of our voting shares following a
merger or reorganization transaction. As part of such a transaction, our existing Directors may resign and new Directors may be appointed
to fill those vacancies without any vote by our stockholders.

 We likely will acquire our participation in a business
opportunity through the issuance of Common Stock or other securities. Although the terms of any such transaction cannot be predicted,
it should be noted that in certain circumstances the criteria for determining whether or not an acquisition is a so-called "tax free"
reorganization under Section 368(a) (1) of the Internal Revenue Code of 1986, as amended (the "Code") depends upon whether the
owners of the acquired business own 80% or more of the voting stock of the surviving entity. If a transaction were structured to take
advantage of these provisions rather than other "tax free" provisions provided under the Code, all prior stockholders would
in that circumstance retain 20% or less of the total issued and outstanding shares of the surviving entity. Under other circumstances,
depending upon the relative negotiating strength of the parties, prior stockholders may retain substantially less than 20% of the total
issued and outstanding shares of the surviving entity. This could result in substantial additional dilution to the equity of those persons
who were our stockholders prior to such reorganization.

 In the case of an acquisition, the transaction may
be accomplished upon the sole determination of management without any vote or approval by stockholders. In the case of a statutory merger
or consolidation directly involving the Company, it will likely be necessary to call a stockholders' meeting and obtain the approval of
the holders of a majority of the outstanding securities. The necessity to obtain such stockholder approval may result in delay and additional
expense in the consummation of any proposed transaction and will also give rise to certain appraisal rights to dissenting stockholders.
Most likely, management will seek to structure any such transaction so as not to require stockholder approval.

 The time and costs required to select and evaluate
a target business and to structure and complete a business combination cannot presently be ascertained with any degree of certainty. Any
costs incurred with respect to the indemnification and evaluation of a prospective business combination that is not ultimately completed
may result in a loss to the Company. Also, fees may be paid in connection with the completion of all types of acquisitions, reorganizations
or mergers. These fees are usually used to pay legal costs, accounting costs, finder's fees, consultant's fees and other related
expenses. In the event that any such fees are paid, they may become a factor in negotiations regarding any potential acquisition or merger
by us. We have no present arrangements or understandings respecting any of these types of fees.

 Significant stockholders may actively negotiate or
otherwise consent to the purchase of all or any portion of their Common Stock as a condition to, or in connection with, a proposed reorganization,
merger or acquisition. It is not anticipated that any such opportunity will be afforded to other stockholders or that such other stockholders
will be afforded the opportunity to approve or consent to any particular stock buy-out transaction. We have not adopted any procedures
or policies for the review, approval or ratification of any related party transactions.

 In the event we merge or acquire a business opportunity,
the successor company will be subject to our reporting obligations. This is commonly referred to as a "back door registration."
A back door registration occurs when a non-reporting company becomes the successor of a reporting company by merger, consolidation, exchange
of securities, acquisition of assets or otherwise. This type of event requires the successor company to file a current report with the
SEC which provides the same kind of information about the company to be acquired that would appear in a registration statement, including
audited and pro forma financial statements. This regulation may eliminate many of the perceived advantages of these types of transactions.
Accordingly, we may incur additional expense to conduct due diligence and present the required information for the business opportunity
in any report.

 Also, the SEC may elect to conduct a full review of
the successor company and may issue substantive comments on the sufficiency of disclosure related to the company to be acquired.

 In addition, regulations also deny the use of Form
S-8 for the registration of securities of a shell company and limit the use of Form S-8 to a reorganized shell company until the expiration
of 60 days from when any such entity is no longer considered to be a shell company. This prohibition could further restrict opportunities
for the Company to acquire companies that may already have stock option plans in place that cover numerous employees. In such an instance,
there may be no exemption from registration for the issuance of securities in any business combination to these employees, thereby necessitating
the filing of a registration statement with the SEC to complete any such reorganization, and incurring the time and expense costs that
are normally avoided by "back door" registrations.

 Competition

 We expect to encounter substantial competition in
our effort to locate attractive business opportunities. Business development companies, venture capital partnerships and corporations,
venture capital affiliates of large industrial and financial companies, small investment companies, and wealthy individuals will be our
primary competition. Many of these entities will have significantly greater experience, resources and managerial capabilities than we
do and will be in a better position than we are to obtain access to attractive business opportunities. We also will experience competition
from other public reporting companies, many of which may have more funds available for such opportunities.

 Effect of Existing or Probable Governmental
Regulations on Business

 We are subject to the Sarbanes-Oxley Act of 2002.
This Act creates a strong and independent accounting oversight board to oversee the conduct of auditors of public companies and to strengthen
auditor independence. It also requires steps to enhance the direct responsibility of senior members of management for financial reporting
and for the quality of financial disclosures made by public companies; establishes clear statutory rules to limit, and to expose to public
view, possible conflicts of interest affecting securities analysts; creates guidelines for audit committee members' appointment,
and compensation and oversight of the work of public companies' auditors; prohibits certain insider trading during pension fund
blackout periods; and establishes a federal crime of securities fraud, among other provisions.

 We are subject to the Securities Exchange Act of 1934
("Exchange Act") and are required to file annual reports on Form 10-K and quarterly reports on Form 10-Q with the SEC on a
regular basis, and will be required to timely disclose certain material events in a Current Report on Form 8-K. We are also subject to
Section 14(a) of the Exchange Act which requires the Company to comply with the rules and regulations of the SEC regarding proxy solicitations,
as outlined in Regulation 14A. Matters submitted to our stockholders at a special or annual meeting of stockholders or pursuant to a written
consent will require us to provide our stockholders with the information outlined in Schedules 14A or 14C of Regulation 14A; preliminary
copies of this information must be submitted to the SEC at least 10 days prior to the date that definitive copies of this information
are forwarded to our stockholders.

 If we acquire a "non-reporting issuer"
under the Exchange Act, we will be subject to the "back-door registration" requirements of the SEC that will require us to
file a Current Report on Form 8-K that will include all information about such "non-reporting issuer" as would have been required
to be filed by that entity had it filed a Form 10 Registration Statement with the SEC.

 Employees

 We currently have no employees. Our management expects
to confer with consultants, attorneys and accountants as necessary. We do not anticipate a need to engage any full-time employees so long
as we are seeking and evaluating business opportunities. We will determine the need for employees based upon a specific business opportunity,
if any.

 Available Information

 We currently do not have a Company website.

 ITEM 1A. RISK FACTORS

 We are a smaller reporting company as defined by Rule
12b-2 of the Securities Exchange Act of 1934 and, as such, we are not required to provide the information for this Item.

 Item 1B. UNRESOLVED STAFF COMMENTS.

 We are a smaller reporting company as defined by Rule
12b-2 of the Securities Exchange Act of 1934 and, as such, we are not required to provide the information for this Item.

 Item 1C. Cybersecurity.

 The Company recognizes the importance of cybersecurity and the potential
risks associated with cyber incidents. As a small entity with simple operations managed solely by our Chief Executive Officer (CEO), we
have not implemented formal cybersecurity policies or procedures. However, we take reasonable steps to protect our electronic data and
ensure the security of our operations.

 Given the size of our company and the nature of our operations, we believe
the risk of significant cybersecurity incidents is minimal. Our CEO is responsible for overseeing all aspects of our business, including
the management of cybersecurity risks. We utilize standard commercial software for business operations, which includes basic security
features such as password protection and data encryption.

 To date, we have not experienced any material cybersecurity incidents,
and there has been no known unauthorized access to our systems. We will continue to monitor our cybersecurity risk profile and take appropriate
actions to safeguard our data and systems.

 Should any material cybersecurity incidents occur,
we will assess the situation and disclose the nature, scope, and potential impact of the incident in accordance with SEC regulations.

 ITEM 2. PROPERTIES

 We do not currently own or lease any property. Until
we pursue a viable business opportunity and recognize income, we will not seek office space.

 ITEM 3. LEGAL PROCEEDINGS

 We are not a party to any legal proceedings as of
the date of this filing.

 ITEM 4. MINE SAFETY DISCLOSURE

 Not applicable to our operations.

 ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY,
RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 Market Information

 Our Common Stock is not listed or quoted to trade
on any public trading market. We do not have any outstanding options or warrants to purchase our securities or securities convertible
into our Common Stock.

 Holders and Dividends

 We had 306 stockholders of record of our Common Stock
as of March 31, 2024. We have not declared dividends on our Common Stock and do not anticipate paying dividends on our Common Stock
in the foreseeable future.

 Recent Sales of Unregistered Securities

 None.

 Issuer Purchase of Securities

 None.

 ITEM 6. [Reserved]

 ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 Executive Overview

 We are an emerging growth company. We recorded non-recurring
revenues related to business development consulting services provided to another company; however, we have not recorded revenues before
or since 2012. We are dependent upon financing to continue basic operations. Management intends to rely upon advances or loans from management,
significant stockholders or third parties to meet our cash requirements, but we have not entered into written agreements guaranteeing
funds and, therefore, no one is obligated to provide funds to us in the future. These factors raise substantial doubt as to our ability
to continue as a going concern. Our plan is to combine with an operating company to generate revenue.

 If we obtain a business opportunity, then it may be
necessary to raise additional capital. We likely will sell our Common Stock to raise this additional capital. We anticipate that we would
issue such stock pursuant to exemptions to the registration requirements provided by federal and state securities laws. The purchasers
and manner of issuance will be determined according to our financial needs and the available exemptions to the registration requirements
of the Securities Act of 1933. We do not currently intend to make a public offering of our stock. We also note that if we issue more shares
of our Common Stock, then our stockholders may experience dilution in the value per share of their Common Stock.

 Liquidity and Capital Resources

 We have not established an ongoing source of revenue
sufficient to cover our operating costs and we expect to rely upon third parties to pay for our operating expenses. At December 31, 2023,
our cash increased to $16,234 compared to $163 at December 31, 2022, as a result of limited financing activities. Our total liabilities
increased to $463,435 at December 31, 2023, from $411,498 at December 31, 2022, primarily due to increases in accrued interest for notes
payable and notes payable for cash advances, consulting services and professional services provided by or paid for by third parties.

 We intend to obtain capital from management, significant
stockholders and third parties to cover minimal operations; however, there is no assurance that additional funding will be available.
Our ability to continue as a going concern during the long term is dependent upon our ability to find a suitable business opportunity
and acquire or enter into a merger with such company. The type of business opportunity with which we acquire or merge will affect our
profitability for the long term.

 During the next 12 months we anticipate incurring
additional costs related to the filing of Exchange Act reports. We believe we will be able to meet these costs through advances and loans
provided by management, significant stockholders or third parties. We may also rely on the issuance of our Common Stock in lieu of cash
to convert debt or pay for expenses.

 Results of Operations

 We had no revenues during 2023 and 2022. General and
administrative expense was $14,929 for 2023 compared to $14,059 for 2022.

 Total other expense increased to $20,937 for 2023
compared to $19,684 for 2022 and represents interest expense on loans payable.

 Our net loss increased to $35,866 for 2023 compared
to $33,743 for 2022. Management expects net losses to continue until we acquire or merge with a business opportunity.

 Commitments and Obligations

 At December 31, 2023 and 2022, we had outstanding
notes payable totaling $286,021 and $255,021, respectively. Accrued interest for notes payable was $171,414 and $150,477 at December 31,
2023 and 2022, respectively. All of the notes payable are non-collateralized, carry interest at 8% and are due on demand. During the years
ended December 31, 2023 and 2022, we borrowed $25,000 and $9,000, respectively, from third parties and recorded interest expense of $20,937
and $19,684 for the years ended December 31, 2023 and 2022, respectively.

 At December 31, 2023, we recorded accounts payable
of $6,000 compared to $6,000 for December 31, 2022.

 On December 31, 2023, we converted $6,000 accounts
payable owed to a third party for 2022 to notes payable, resulting in total accounts payable of $6,000 at December 31, 2023.

 On December 31, 2022, we converted $6,000 accounts
payable owed to a third party for 2021 to notes payable, resulting in total accounts payable of $6,000 at December 31, 2022.

 Two lenders represent in excess of 95% of the Company's
accounts payable and notes payable at December 31, 2023 and 2022.

 Off-Balance Sheet Arrangements

 We have not entered into any off-balance sheet arrangements
that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues
or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.

 Emerging Growth Company

 We qualify as an emerging growth company as that term
is used in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). A company qualifies as an emerging growth company
if it has total annual gross revenues of less than $1.07 billion during its most recently completed fiscal year and, as of December 8,
2011, had not sold common equity securities under a registration statement. Under the JOBS Act we are permitted to, and intend to, rely
on exemptions from certain disclosure requirements.

 In addition, Section 107 of the JOBS Act also provides
that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities
Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain
accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits
of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such
new or revised accounting standards.

 ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY
DATA

 SKINOVATION PHARMACEUTICAL INCORPORATED

 Financial Statements

 December 31, 2023 and 2022

 Report of Independent Registered
Public Accounting Firm, Pinnacle Accountancy Group of Utah (PCAOB ID 6117)

 Report of Independent Registered Public
Accounting Firm - Fruci & Associates II, PLLC

 Balance Sheets

 Statements of Operations

 Statements of Stockholders' Deficit

 Statements of Cash Flows

 Notes to the Financial Statements

 REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM

 To the Board of Directors and Stockholders

 Salt Lake City, Utah

 Opinion on the Financial Statements

 We have audited the accompanying balance sheets
of Skinovation Pharmaceutical Incorporated (the Company) as of December 31, 2022, and the related statements of operations, stockholders'
deficit, and cash flows for the year then ended, and the related notes (collectively referred to as the financial statements). In our
opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022,
and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted
in the United States of America.

 Consideration of the Company's Ability
to Continue as a Going Concern

 The accompanying financial statements have been
prepared assuming that the Company will continue as a going concern. The Company has suffered recurring losses and has no operations
which raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters
are described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 Basis for Opinion

 These financial statements are the responsibility
of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our
audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required
to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations
of the Securities and Exchange Commission and the PCAOB.

 We conducted our audit in accordance with the standards
of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform,
an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal
control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal
control over financial reporting. Accordingly, we express no such opinion.

 Our audit included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

 /s/ Pinnacle Accountancy Group of Utah

 We have served as the Company's auditor since 2017.

 Pinnacle Accountancy Group of Utah

 Farmington, Utah

 March 24, 2023

 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM

 To the Board of Directors and Stockholders of Skinovation
Pharmaceutical Inc.

 Opinion on the Financial Statements

 We have audited the accompanying balance sheet
of Skinovation Pharmaceutical Inc. ("the Company") as of December 31, 2023 and the related statements of operations, stockholders'
deficit, and cash flows for the year ended December 31, 2023, and the related notes (collectively referred to as the financial statements).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2023 and the results of its operations and its cash flows for the year ended December 31, 2023, in conformity with accounting principles
generally accepted in the United States of America.

 Going Concern

 The accompanying financial statements have
been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company
has limited assets, negative working capital, and net losses since inception. These factors, among others, raise substantial doubt about
the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in
Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 Basis for Opinion

 These financial statements are the responsibility
of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our
audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required
to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations
of the Securities and Exchange Commission and the PCAOB.

 We conducted our audit in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding
of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company's
internal control over financial reporting. Accordingly, we express no such opinion.

 Our audit included performing procedures to
assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

 Critical Audit Matters

 Critical audit matters are matters arising
from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee
and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging,
subjective, or complex judgments. We determined that there were no critical audit matters.

 Fruci & Associates II, PLLC – PCAOB ID #0 5525

 We have served as the Company's auditor since 2024.

 Spokane, Washington

 April 10, 2024

 Balance Sheets

 DEC 31, 2023

 DEC 31, 2022

 ASSETS

 Current Assets

 Cash

 $

 $

 Total Current Assets

 Total Assets

 $

 $

 LIABILITIES AND STOCKHOLDERS' DEFICIT

 Current Liabilities

 Accounts payable

 $
 6,000

 $
 6,000

 Notes payable

 286,021

 255,021

 Accrued interest

 171,414

 150,477

 Total Current Liabilities

 463,435

 411,498

 Total Liabilities

 463,435

 411,498

 Commitments and Contingencies

 Stockholders' Deficit

 Preferred stock, $.001 par value; 25,000,000 shares
authorized; 0 shares issued and outstanding

 —

 —

 Common stock, $.001 par value; 50,000,000 shares
authorized; 708,000 shares issued and outstanding

 Additional paid in capital

 Accumulated deficit

 ( 473,057
)

 ( 437,191
)

 Total Stockholders' Deficit

 ( 447,201
)

 ( 411,335
)

 Total Liabilities and Stockholders' Deficit

 $

 $

 The accompanying notes are an integral part of these
financial statements

 Statements of Operations

 FOR THE YEAR ENDED
DEC 31, 2023

 FOR THE YEAR ENDED
DEC 31, 2022

 REVENUES

 $
 —

 $
 —

 OPERATING EXPENSES

 General and administrative

 14,929

 14,059

 TOTAL OPERATING EXPENSES

 14,929

 14,059

 LOSS FROM OPERATIONS

 ( 14,929
)

 ( 14,059
)

 OTHER INCOME (EXPENSE)

 Interest expense

 ( 20,937
)

 ( 19,684
)

 TOTAL OTHER INCOME (EXPENSE)

 ( 20,937
)

 ( 19,684
)

 LOSS BEFORE INCOME TAXES

)

)

 INCOME TAX EXPENSE

 —

 —

 NET LOSS

 $
)

 $
)

 Basic and diluted net loss per share

 $
 ( 0.05
)

 $
 ( 0.05
)

 Basic and diluted weighted average shares outstanding

 The accompanying notes are an integral part of these
financial statements.

 Statements of
Stockholders' Deficit

 For the years ended December
31, 2023 and 2022

 Additional

 Total

 Common Stock

 Paid-in

 Accumulated

 Stockholders'

 Shares

 Amount

 Capital

 Deficit

 Deficit

 Balance – December 31, 2021

 $

 $
 ( 403,448
)

 $
 ( 377,592
)

 Net loss for the year ended December 31, 2022

 —

 —

 —

)

)

 Balance – December 31, 2022

 $

 $
 ( 437,191
)

 $
 ( 411,335
)

 Net loss for the year ended December 31, 2023

 —

 —

 —

)

)

 Balance – December 31, 2023

 $

 $
 ( 473,057
)

 $
 ( 447,201
)

 The accompanying notes
are an integral part of these financial statements.

 Statements of Cash Flows

 FOR THE YEAR ENDED
DEC 31, 2023

 FOR THE YEAR ENDED
DEC 31, 2022

 Cash Flows from Operating Activities

 Net loss

 $
)

 $
)

 Adjustments to reconcile net loss to
 net cash used by operating activities:

 Changes in operating assets and liabilities:

 Increase in accounts payable

 6,000

 5,000

 Increase in accrued interest

 20,937

 19,684

 Net cash used by operating activities

 ( 8,929
)

 ( 9,059
)

 Cash Flows from Investing Activities

 Net cash used by investing activities

 —

 —

 Cash Flows from Financing Activities

 Proceeds from notes payable

 25,000

 9,000

 Net cash provided by financing activities

 25,000

 9,000

 Increase (decrease) in cash

 16,071

 ( 59
)

 Cash and cash equivalents at beginning of year

 Cash and cash equivalents at end of year

 $

 $

 Supplemental Cash Flow Information:

 Cash paid for interest

 $
 —

 $
 —

 Cash paid for income taxes

 $
 —

 $
 —

 Non-Cash Investing and Financing Activities

 Conversion of accounts payable to notes payable

 $
 6,000

 $
 6,000

 The accompanying notes are an integral part of these
financial statements

 Notes to the Financial Statements

 December 31, 2023 and 2022

 NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 a. Organization & Summary of
Significant Accounting Policies

 The Company was incorporated under the laws of the
state of Nevada on January 15, 1988, as Data Financial Corporation. The Company changed its name to Skinovation Pharmaceutical Incorporated
on August 5, 1992. On November 23, 2016, the Company changed its domicile from Nevada to Wyoming

 b. Cash and Cash Equivalents

 The Company considers all highly liquid investments
with maturities of three months or less to be cash equivalents.

 c. Use of estimates

 The preparation of financial statements in conformity
with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 d. Earnings Per Share

 The computation of earnings per share of Common Stock
is based on the weighted average number of shares outstanding at the date of the financial statements.

 For the Years Ended
December 31,

 2023

 2022

 Net Loss (numerator)

 $
)

 $
)

 Weighted Average Number of Shares Outstanding (denominator)

 Basic Loss per Common Share

 $
 0.05

 $
 ( 0.05
)

 For the years ended December 31, 2023 and 2022, the
Company had no potentially dilutive Common Stock equivalents issued.

 e. Concentrations of Risk

 Two lenders represent in excess of 95 % of the Company's Accounts
Payable and Notes Payable for the fiscal years ended December 31, 2023, and December 31, 2022.

 f. Recent Pronouncements

 The Company
has evaluated Recent Accounting Pronouncements and has determined that all such pronouncements either do not apply or their impact is
insignificant to the financial statements.

 g. Fair
Value Measurements

 If required by authoritative literature, the Company
would account for certain assets and liabilities at fair value.

 The cash, accounts payable, notes payable and accrued
interest have fair values that approximate their carrying values due to the short-term nature of these instruments

 If required by authoritative literature, the Company
would account for certain assets and liabilities at fair value.

 The cash, accounts payable, notes payable and accrued
interest have fair values that approximate their carrying values due to the short-term nature of these instruments.

 NOTE 2 - GOING CONCERN

 The accompanying financial statements have been prepared
assuming that the Company will continue as a going concern. The Company has limited assets, has a negative working capital of $ 447,201 and has incurred losses of $ 473,057 since inception. Its activities have been limited for the past several years and it is dependent upon
financing to continue operations. These factors raise substantial doubt about the ability of the Company to continue as a going concern.
The financial statements do not include any adjustments that might result from the outcome of this uncertainty. It is management's
plan to acquire or merge with other operating companies.

 NOTE 3 - INCOME TAXES

 The Company follows FASB ASC 740 which requires
a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical
merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount
to recognize in the financial statements.

 Deferred taxes are provided on a liability method
whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry-forwards and deferred
tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported
amounts of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when, in the opinion of
management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and
liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

 The Company currently has no issues creating timing
differences that would mandate deferred tax expense. Net operating losses would create possible tax assets in future years. Due to the
uncertainty of the utilization of net operating loss carry forwards, a valuation allowance has been made to the extent of any tax benefit
that net operating losses may generate. A provision for income taxes has not been made due to net operating loss carry-forwards
of $ 473,057 and $ 437,191 as of December 31, 2023, and December 31, 2022, respectively, which may be offset against future taxable income
through 2037. No tax benefit has been reported in the financial statements.

 Deferred tax asset and the valuation account are
as follows at December 31, 2023 and 2022:

 For the Years Ended
December 31,

 2023

 2022

 Net operating loss carryforward (at 21%)

 $
 99,342

 $
 91,810

 Valuation allowance

 ( 99,342
)

 ( 91,810
)

 Deferred tax asset

 $
 —

 $
 —

 The change in the valuation allowance was $ 7,532 during the year ended
December 31, 2023.

 A reconciliation of amounts obtained by applying
the Federal tax rate of 21% to pre-tax income to income tax benefit is as follows:

 For the Years Ended
December 31,

 2023

 2022

 Federal tax benefit (at 21%)

 $
 7,532

 $
 7,086

 Change in valuation allowance

 ( 7,532
)

 ( 7,086
)

 $
 —

 $
 —

 The Company did not have any tax positions for
which it is reasonably possible that the total amount of unrecognized tax benefits will significantly increase or decrease within the
next 12 months.

 The Company includes interest and penalties arising
from the underpayment of income taxes in the statements of operations in the provision for income taxes. As of December 31, 2023
and 2022, the Company had no accrued interest or penalties related to uncertain tax positions.

 The tax years that remain subject to examination
by major taxing jurisdictions are those for the years ended December 31, 2023, 2022, 2021, and 2020.

 NOTE 4 - ACCOUNTS AND NOTES PAYABLE

 At December 31, 2023 and 2022, the Company reported
accounts payable of $ 6,000 and $ 6,000, respectively, and notes payable of $ 286,021 and $ 255,021 for services as well as cash advances
received from unrelated parties. The notes payable bear interest at 8 % and are due on demand. The accounts payable for services each year
may be converted to loans at the end of the following year. Accounts payable of $ 6,000 and $ 6,000 were converted to notes payable at December
31, 2023 and 2022, respectively.

 Accrued interest was $ 171,414 and $ 150,477 at
December 31, 2023 and 2022, respectively.

 NOTE 5 - STOCK TRANSACTIONS

 The Company did not issue any Common Stock, options,
warrants or any other stock-based awards subsequent in 2023 and 2022.

 NOTE 6 – SUBSEQUENT EVENTS

 The Company
has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and has determined
that there are no such events that would have a material impact on the financial statements.

 ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
ON ACCOUNTING AND FINANCIAL DISCLO SURE

 On January 3, 2024,
the Board of Directors (the "Board") of Skinovation Pharmaceutical Incorporated ("Skinovation" or the "Company")
agreed to dismiss the Company's independent registered public accounting firm, Pinnacle Accountancy Group of Utah ("Pinnacle"),
effective as of January 3, 2024. Also on January 3, 2024, the Company engaged the accounting firm of Fruci & Associates II, PLLC
as the Company's new independent registered public accounting firm. The Board and the Company's Audit Committee approved
of the dismissal of Pinnacle and the engagement of Fruci & Associates II, PLLC.

 ITEM 9A. CONTROLS
AND PROCEDURES

 Disclosure Controls
and Procedures

 We maintain disclosure
controls and procedures that are designed to ensure that information required to be disclosed in our filings under the Exchange Act is
recorded, processed, summarized and reported within the periods specified in the rules and forms of the SEC. This information is accumulated
to allow timely decisions regarding required disclosure. Our President, who serves as our principal executive officer and principal financial
officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report and
he determined that our disclosure controls and procedures were ineffective due to a control deficiency. During the period we did not
have additional personnel to allow segregation of duties to ensure the completeness or accuracy of our information. Due to the size and
operations of the Company we are unable to remediate this deficiency until we acquire or merge with another company.

 Management's
Annual Report on Internal Control over Financial Reporting

 Management is responsible
to establish and maintain adequate internal control over financial reporting. Our principal executive officer is responsible to design
or supervise a process that provides reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles. The policies and procedures include:

 maintain records in reasonable detail to accurately and fairly
reflect the transactions and dispositions of assets,

 provide reasonable assurance that transactions are recorded
as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts
and expenditures are being made only in accordance with authorizations of management and Directors, and

 provide reasonable assurance regarding prevention or timely
detection of unauthorized acquisition, use or disposition of assets that could have a material effect on our financial statements.

 For the year ended
December 31, 2023, management has relied on the Committee of Sponsoring Organizations of the Treadway Commission (COSO - 2013), "Internal
Control - Integrated Framework," to evaluate the effectiveness of our internal control over financial reporting. Based upon that
framework, management has determined that our internal control over financial reporting is ineffective due to the lack of additional
personnel to allow segregation of duties to ensure the completeness or accuracy of our information.

 Our management determined
that there were no changes made in our internal controls over financial reporting during the fourth quarter of 2023 that have materially
affected or are reasonably likely to materially affect our internal control over financial reporting.

 ITEM 9B. OTHER INFORMATION

 No ne.

 ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE
GOVERNANCE

 Directors and Executive Officers

 Our Directors and executive officer and their respective
ages, positions and biographical information are presented below. Our Bylaws require three Directors who serve for terms of one year or
until they are replaced by a qualified Director. We currently have one vacancy on our Board of Directors. Our executive officers are chosen
by our Board of Directors and serve at its discretion. There are no existing family relationships between or among any of our executive
officers or Directors.

 Name

 Age

 Position Held

 Director Term

 Hugo Rodier

 Director and President

 May 2009 until our next annual meeting.

 M. Jeanne Ball

 Director and Secretary/Treasurer

 March 1998 until our next annual meeting.

 Hugo Rodier – From 2000 to the
present Mr. Rodier has been a Medical Director with Pioneer Comprehensive Clinic located in Draper, Utah. In addition, since 2002, he
has been an adjunct professor of Family and Preventive Medicine and a member of the Utah School of Medicine Admissions Committee at the
University of Utah. He received his medical degree from the University of Utah, School of Medicine.

 M. Jeanne Ball – Ms. Ball works
as an independent contractor performing duties of a legal assistant for attorneys. She has experience serving in management positions
for public reporting companies which may prove significant in our search for a business opportunity and may be critical to our operations
moving forward.

 During the past ten years, none of our executive officers
have been involved in any legal proceedings that are material to an evaluation of their ability or integrity; namely: (1) filed a petition
under federal bankruptcy laws or any state insolvency laws, nor had a receiver, fiscal agent or similar officer appointed by a court for
the business or property of such person, or any partnership in which he/she was a general partner at or within two years before the time
of such filing, or any corporation or business association of which he/she was an executive officer at or within two years before the
time of such filing; (2) been convicted in a criminal proceeding or named subject to a pending criminal proceeding (excluding traffic
violations and other minor offenses); (3) been the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated,
of any court of competent jurisdiction, permanently or temporarily enjoining him or her from or otherwise limiting his/her involvement
in any type of business, securities or banking activities; or (4) been found by a court of competent jurisdiction in a civil action, by
the SEC or the Commodity Futures Trading Commission to have violated any federal or state securities law, and the judgment in such civil
action or finding by the SEC has not been subsequently reversed, suspended, or vacated.

 Code of Ethics

 Since we have only two persons serving as executive
officers and Directors, and because we have minimal operations, we have not adopted a code of ethics for our principal executive and financial
officers. Our Board of Directors will revisit this issue in the future to determine if adoption of a code of ethics is appropriate. In
the meantime, our management intends to promote honest and ethical conduct, full and fair disclosure in our reports to the SEC and comply
with applicable governmental laws and regulations.

 Corporate Governance

 We are a smaller reporting company with minimal operations
and only two Directors and executive officers. As a result, we do not have a standing nominating committee for Directors, nor do we have
an audit committee with an audit committee financial expert serving on that committee. Our entire Board of Directors acts as our nominating
and audit committee.

 ITEM 11. EXECUTIVE COMPENSATION

 Executive Officer Compensation

 None of our named executive officers received any
cash or non-cash compensation from us during the past two fiscal years, and none had outstanding equity awards at year end. We have not
entered into employment contracts with our executive officers and their compensation, if any, will be determined at the discretion of
our Board of Directors.

 We do not offer retirement benefit plans to our executive
officers, nor have we entered into any contract, agreement, plan or arrangement, whether written or unwritten, that provides for payments
to a named executive officer at, or in connection with, the resignation, retirement or other termination of a named executive officer,
or a change in control of the company or a change in the named executive officer's responsibilities following a change in control.

 Compensation of Directors

 We do not have any standard arrangement for compensation
of our Directors for any services provided as Director, including services for committee participation or for special assignments.

 ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 Securities Under Equity Compensation Plans

 None.

 Beneficial Ownership

 The following tables set forth the beneficial ownership
of our outstanding Common Stock of our management and of each person or group known by us to own beneficially more than 5% of our voting
stock. We have not issued any shares of Preferred Stock. Beneficial ownership is determined in accordance with the rules of the SEC and
generally includes voting or investment power with respect to securities. Except as indicated by footnote, the persons named in the table
below have sole voting power and investment power with respect to all shares of Common Stock shown as beneficially owned by them. The
percentage of beneficial ownership is based on 708,000 shares of Common Stock outstanding as of March ____, 2024.

 CERTAIN BENEFICIAL OWNERS

 Name and address of beneficial owner

 Amount and nature

 of beneficial ownership

 Percent

 of class

 Donald R. Mayer

 6 East North Lane

 Sandy, Utah 84092

 250,000

 35.3

 National Financial Services Corporation

 200 Liberty Street

 One World Financial Center

 New York, New York 10281

 50,000

 7.1

 Arthur Candland

 5295 S. 300 W., Suite 499

 Murray, Utah 84107

 44,000

 6.2

 MANAGEMENT

 Name of beneficial owner

 Amount and nature

 of beneficial ownership

 Percent

 of class

 M. Jeanne Ball

 10,000

 1.4

 Directors and officers as a group

 10,000

 1.4

 ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS,
AND DIRECTOR INDEPENDENCE

 Transactions with Related Parties

 During the past two fiscal years through the date
of this report we have not engaged in, or propose to engage in, any transactions involving our executive officers, Directors, 5% or more
stockholders or immediate family members of such persons.

 Director Independence

 None of our Directors are independent Directors as
defined by NASDAQ Stock Market Rule 5605(a)(2). This rule defines persons as "independent" who are neither officers nor employees
of the company and have no relationships that, in the opinion of the Board, would interfere with the exercise of independent judgment
in carrying out their responsibilities as Directors.

 ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

 Auditor Fees

 The following table presents the aggregate fees billed
by our principal accounting firm, Fruci & Associates II, PLLC for 2023 audit only and Pinnacle Accountancy Group of Utah for the 2022
audit and 2023 10-Q reviews.

 in connection with the audit of our financial statements
and other professional services for each of the last two fiscal years.

 Fruci & Associates II, PLLC.

 Pinnacle Accountancy Group of Utah

 2023

 2023/2022

 Audit fees

 $
 6,000

 $
 7,100

 Audit-related fees

 —

 —

 Tax fees

 —

 —

 All other fees

 $
 —

 $
 —

 Audit fees represent fees for professional services
rendered by our principal accountants for the audit of our annual financial statements and review of the financial statements included
in our Forms 10-Q or services that are normally provided by our principal accountants in connection with statutory and regulatory filings
or engagements.

 Audit-related fees represent professional services
rendered for assurance and related services by the accounting firm that are reasonably related to the performance of the audit or review
of our financial statements that are not reported under audit fees.

 Tax fees represent professional services rendered
by the accounting firm for tax compliance, tax advice, and tax planning.

 All other fees represent fees billed for products
and services provided by the accounting firm, other than the services reported for the other three categories.

 Pre-approval Policies

 We do not have an audit committee currently serving
and as a result our Board of Directors performs the duties of an audit committee. Our Board of Directors will evaluate and approve in
advance the scope and cost of the engagement of an auditor. All services rendered by our principal accountant are performed pursuant to
a written engagement letter between us and the principal accountant. We do not rely on pre-approval policies and procedures.

 ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

 (a)(1) Financial Statements

 The audited financial statements of Skinovation Pharmaceutical
Incorporated are included in this report under Item 8 on pages 17 through 25.

 (a)(2) Financial Statement Schedules

 All financial statement schedules are included in
the footnotes to the financial statements or are inapplicable or not required.

 (a)(3) Exhibits

 The following documents have been filed as part of
this report.

 Exhibit No.

 Description

 3(i).1

 Articles of Incorporation (Incorporated
by reference to exhibit 3.1 of the Form 10-KSB, filed March 29, 2002)

 3(i).2

 Wyoming Articles of Domestication, filed November 23, 2016 (Incorporated
by reference to exhibit 3(i).2 of Form 10-K, filed March 20, 2017)

 3(ii)

 Bylaws of Skinovation (Incorporated by reference to exhibit 3(ii)
of Form 10-K, filed March 20, 2017)

 4.6

 Description of Securities (Incorporated by reference to exhibit 4.6
of Form 10-K, filed July 10, 2020)

 31.1

 Principal Executive Officer Certification

 31.2

 Principal Financial Officer Certification

 32.1

 Section 1350 Certification

 101.INS

 101.SCH

 101.CAL

 101.DEF

 101.LAB

 101.PRE

 SIGNATURES

 Pursuant to the requirements of the Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, there unto duly authorized

 SKINOVATION PHARMACEUTICAL INCORPORATED

 By: /s/ Hugo Rodier

 Hugo Rodier, President

 Date: April 15, 2024

 Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 By: /s/Hugo Rodier

 Hugo Rodier

 Director and President

 Principal Executive Officer

 Principal Financial Officer

 Date: April 15, 2024

 By: /s/ M. Jeanne Ball

 M. Jeanne Ball

 Director and Secretary/Treasurer

 Date: April 15, 2024